106 related articles for article (PubMed ID: 22442273)
1. The changes in plasma serotonin levels after hormone therapy and their relationship with estrogen responsiveness on bone in postmenopausal women.
Kim HY; Park MH; Yoon HK; Han KO
J Clin Endocrinol Metab; 2012 Jun; 97(6):1986-94. PubMed ID: 22442273
[TBL] [Abstract][Full Text] [Related]
2. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
3. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
5. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
6. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
10. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
11. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
Greenspan SL; Resnick NM; Parker RA
J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
[TBL] [Abstract][Full Text] [Related]
12. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
13. Undercarboxylated osteocalcin concentration in postmenopausal women receiving hormone therapy daily and on alternate days.
Yasui T; Uemura H; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
Menopause; 2006; 13(2):314-22. PubMed ID: 16645545
[TBL] [Abstract][Full Text] [Related]
14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
[TBL] [Abstract][Full Text] [Related]
16. Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women.
Luengratsameerung S; Panyakhamlerd K; Treratanachat S; Taechakraichana N
Climacteric; 2013 Feb; 16(1):133-40. PubMed ID: 22515801
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
18. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
19. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
Rapuri PB; Gallagher JC; Knezetic JA; Haynatzka V
Maturitas; 2006 Mar; 53(4):371-9. PubMed ID: 16139450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
